Solid dispersoid of EED inhibitor, oral preparation containing solid dispersoid and preparation method of solid dispersoid
By combining EED inhibitors with carriers such as hydroxypropylmethylcellulose acetate succinate and Eudragit, a stable solid dispersion was formed, which solved the problem of low dissolution of EED inhibitors in gastrointestinal fluid and significantly improved their biological properties Utilization and therapeutic effect.
Patent Information
- Application Number
- CN202410733007.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-06
- Filing Date
- 2024-06-06
- Publication Date
- 2024-12-06
AI Technical Summary
The existing EED inhibitor compound A has low dissolution in gastrointestinal fluid, resulting in low bioavailability, and new dosage forms and processes are needed to improve its dissolution and absorption in the gastrointestinal tract.
A stable solid dispersion containing EED inhibitors was developed to form a solid dispersion combination by combining with polymer carriers such as hydroxypropyl cellulose acetate succinate (HPMCAS) and polyacrylic resins such as Eudragit to improve its solubility and absorption in gastrointestinal fluid.
It significantly improves the bioavailability of EED inhibitors, ensures its high solubility and stability in gastrointestinal fluid, and achieves more effective drug absorption and therapeutic effects.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical preparations, and specifically relates to a solid dispersion having good solubility and good bioavailability and comprising an embryonic ectodermal development protein (EED) inhibitor, a solid dispersion composition comprising the solid dispersion and an excipient, an oral preparation comprising the solid dispersion or the solid dispersion composition and a preparation method thereof, and use of the solid dispersion, the solid dispersion composition or the oral preparation for treating and / or preventing EED-mediated diseases. Technical Background
[0002] Polycomb family (PcG) proteins are a group of transcriptional repressors that regulate target genes through chromatin modification. They not only control the normal developmental pattern of individuals, but are also closely related to cell proliferation, differentiation and tumorigenesis. PcG proteins can be divided into two major categories: PRC1 (polycomb repressive complex 1, with E3 ubiquitin ligase activity) and PRC2 (polycomb repressive complex 2, with methyltransferase activity).
[0003] PRC2, as a representative member of PcG, is a multi-subunit complex that maintains the repressive state of chromatin by silencing specific gene expression. It plays a key role in development, tissue differentiation and regeneration. Its core subunits include histone methyltransferase 2 (EZH2), EED, suppressor of zeste 12 (SUZ12) and retinoblastoma suppressor-associated protein 46 / 48 (RbAp46 / 48). PRC2 dysregulation has been found in many human cancers. For example, EZH2 is highly expressed in a variety of human cancers and promotes cancer occurrence and malignant transformation. EZH2 mutations occur in up to 25% of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) and are associated with poor patient prognosis.
[0004] Targeted inhibition of the methyltransferase activity of EZH2 has been shown to be a successful cancer treatment strategy. However, secondary mutations of EZH2 can produce acquired drug resistance, and its homolog EZH1 also has methyltransferase activity, which can lead to limited activity of EZH2 inhibitors. EED can activate the methyltransferase activity of EZH2, so allosteric targeted inhibition of EED is also an effective anti-cancer method, and can produce stronger anti-tumor effects by overcoming resistance to EZH2 inhibitors and inhibiting EZH2 and EZH1 at the same time. Previous research results have indeed shown that EED inhibitors have great therapeutic potential in hematological tumors, solid tumors and non-tumor indications.
[0005] So far, EED inhibitors that have entered clinical research include MAK683 developed by Novartis and FTX-6058 developed by Fulcrum Therapeutics. In addition, there is a new type of potent and selective small molecule EED inhibitor under development by Ascentage Pharmaceuticals, which has a high EED binding affinity and is expected to overcome tumor resistance and achieve complete and lasting tumor regression by regulating tumor epigenetics and tumor microenvironment. The compound has obtained clinical trial authorization from the US FDA and the China National Medical Products Administration (NMPA) Drug Review Center (CDE) on June 29 and November 10, 2022, respectively, to conduct a Phase I clinical trial for the treatment of advanced solid tumors or hematological malignancies. It is also the first original EED inhibitor to enter the clinical stage in China.
[0006] The compound with the chemical name of 12-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-4-isopropyl-7-(trifluoromethyl)-4,5-dihydro-3H-2,4,8,11,12a-pentaazabenzo[4,5]cycloocta[1,2,3-cd]inden-3-one is a member of a group of imidazopyrimidine EED inhibitors disclosed in WO2021 / 011713 (CN114127073A), and the structural formula is as follows:
[0007] (hereinafter referred to as "Compound A")
[0008] Preclinical data have demonstrated that compound A has in vitro anti-tumor cell proliferation activity in multiple tumor cell lines, as well as anti-tumor activity in PDX / CDX models of EZH2-mutated B-cell non-Hodgkin's lymphoma, INI1-negative malignant rhabdoid tumor, BAP1-mutated mesothelioma, and prostate cancer.
[0009] In view of the great therapeutic potential of EED inhibitors in the field of tumor treatment, the early development of EED inhibitor pharmaceutical preparations that are easy to prepare, convenient to use, and have good formulation properties can benefit more tumor patients as soon as possible. At the same time, in view of the long-standing safety issues in the field of tumor treatment drugs, namely toxic side effects, there is also a great demand in practice for anticancer drugs with enhanced bioavailability, which can exert therapeutic effects at lower doses.
[0010] The raw material of compound A is anhydrous crystalline powder, which is slightly hygroscopic and almost insoluble in water. Its solubility in aqueous buffer solution of pH 1.2 to 7.4 is 0.39 to 0.08 micrograms / mL (37°C / 24h), and its fluidity is poor. For such poorly water-soluble drugs, the dissolution of the drug in gastrointestinal fluid is the rate-limiting step of its bioavailability. Poor water solubility will inevitably lead to low solubility, which in turn leads to lower bioavailability. Therefore, if the bioavailability of the drug is to be improved, it is necessary to specially design the dosage form, prescription composition and process to change the dispersion state of the drug and promote its dissolution in the gastrointestinal tract.
[0011] In order to meet the above needs and solve the above problems, the inventors have developed a stable EED inhibitor solid dispersion that can provide good solubility and good bioavailability after extensive research and screening, and prepared the solid dispersion into an oral preparation with good formulation properties through prescription design, thereby achieving the purpose of the invention. SUMMARY OF THE INVENTION
[0013] In one aspect, the present invention provides a stable solid dispersion of an EED inhibitor (particularly Compound A) and a carrier material with good dissolution and bioavailability.
[0014] In another aspect, the present invention provides a stable solid dispersion composition having good dissolution and bioavailability, comprising the solid dispersion of the present invention and one or more pharmaceutically acceptable excipients.
[0015] In another aspect, the present invention provides an oral formulation (eg, tablet) having good dissolution and bioavailability, comprising the solid dispersion or solid dispersion composition of the present invention, wherein the EED inhibitor is in the solid dispersion.
[0016] In another aspect, the present invention provides a method for preparing the solid dispersion of the present invention.
[0017] In another aspect, the present invention provides a method for preparing the oral formulation of the present invention.
[0018] In another aspect, the present invention provides a method for treating or preventing a disease (eg, cancer or tumor) for which inhibition of EED provides benefits, comprising administering a therapeutically effective amount of a solid dispersion, solid dispersion composition, or oral formulation of the present invention to a subject in need thereof.
[0019] In another aspect, the present invention provides use of the solid dispersion, solid dispersion composition or oral formulation of the present invention for treating or preventing a disease that benefits from EED inhibition (eg, cancer or tumor).
[0020] In another aspect, the present invention provides use of the solid dispersion, solid dispersion composition or oral formulation of the present invention in the preparation of a medicament for treating or preventing a disease (eg, cancer or tumor) for which inhibition of EED provides benefits. DETAILED DESCRIPTION OF THE INVENTION
[0022] definition
[0023] The term "about" as used herein will fluctuate the numerical value associated with it by ±10%. For ratios, the term "about" is used to qualify each digit of the given ratio. For example, a ratio of about 1:1 means a ratio of 0.9-1.1:0.9-1.1.
[0024] "Solid dispersion" refers to a highly dispersed system formed by uniformly dispersing drugs in molecular, colloidal, amorphous, microcrystalline and other highly dispersed states in inactive excipients or carriers. Its characteristics include delaying the hydrolysis and oxidation of drugs, masking bad odors and irritation, solidifying liquid drugs, accelerating or delaying the dissolution of drugs, and achieving the purpose of rapid release or sustained release. However, the highly dispersed state also brings about the problem of poor physical stability of solid dispersions and easy aging after long-term storage.
[0025] Due to differences in carrier materials, preparation methods, composition ratios, etc., there are different types of solid dispersions, including but not limited to simple eutectic mixtures, solid solutions, and coprecipitates. There are many methods for preparing solid dispersions, including melting methods, solvent methods, solvent-melting methods, solvent-spray drying methods, grinding methods, etc. The means for verifying and analyzing the presence of drugs and identifying the formation of solid dispersions include thermal analysis (including differential thermal analysis (DTA) or differential scanning calorimetry (DSC)), X-ray diffraction (XRPD), infrared spectroscopy, polarizing microscopy (PLM), etc.
[0026] However, in view of the diversity of carrier material types and properties, the diversity of preparation methods, and the frequent incompatibility between carrier materials and preparation methods and specific drug molecules, the advantages of the above-mentioned solid dispersions are often not realized. In other words, it is often impossible to obtain a solid dispersion that can bring good formulation properties based solely on the molecular structure and physicochemical properties of a specific drug and conventional technical means of solid dispersions.
[0027] "Solid dispersion carrier" is the material in which the drug is dispersed in a highly dispersed state such as molecular, colloidal, amorphous, or microcrystalline in the solid dispersion. The properties of the carrier material have a great influence on the properties of the solid dispersion. It should have basic properties such as being non-toxic, non-carcinogenic, not affecting the stability of the drug, not undergoing chemical changes with the drug, and not affecting the efficacy and content monitoring of the drug.
[0028] Commonly used solid dispersion carrier materials can be divided into: water-soluble carrier materials, including polyethylene glycol (PEG), polyvinyl pyrrolidone (PVP), surfactants, organic acids, sugars (alcohols), etc.; poorly soluble carrier materials, including cellulose, polyacrylic acid resins, lipids, etc.; enteric carrier materials, including enteric cellulose and polyacrylic acid resins, etc. It is generally believed that water-soluble carriers can increase the solubility and dissolution rate of poorly soluble drugs, which helps to improve the bioavailability of drugs; poorly soluble carriers can delay or control drug release; enteric carriers can control drug release in the small intestine.
[0029] Among them, polyethylene glycol carriers are one of the most commonly used water-soluble carriers, characterized by low toxicity, low melting point, and good water solubility. After being made into solid dispersions, they can disperse drug molecules in a molecular state, thereby accelerating the dissolution rate of the drug. Generally, PEG with a molecular weight of 1000-20000 is selected as a solid dispersion carrier, and the most commonly used are PEG4000 and PEG6000.
[0030] Povidone carriers are amorphous high molecular polymers that are heat stable, easily soluble in polar organic solvents such as water and ethanol, and have a strong inhibitory effect on a variety of drugs.
[0031] Polyacrylic acid resin carriers are a general term for copolymers of acrylic acid, methacrylic acid and their derivatives. The most commonly used product is called Eudragit, which includes methacrylic acid copolymers and methacrylate copolymers. Different models are available according to different compositions, proportions and polymerization degrees. Eudragit E is a copolymer of dimethylaminoethyl methacrylate and other neutral methacrylates, and Eudragit L and Eudragit S are copolymers of methacrylic acid and acrylic esters in different proportions, including methacrylic acid-ethyl acrylate (1:1) copolymer, methacrylic acid-methyl methacrylate (1:1) copolymer, and methacrylic acid-methyl methacrylate (1:2) copolymer. Specific examples include, but are not limited to, Eudragit E100, Eudragit EPO, Eudragit L100-55, Eudragit L30D-55, Eudragit L100, Eudragit S100, etc.
[0032] Examples of cellulose carriers include ethyl cellulose, hydroxypropyl cellulose, and hypromellose, and also include enteric celluloses such as cellulose acetate phthalate, hypromellose phthalate, and hypromellose acetate succinate.
[0033] The term "preparation" or "pharmaceutical composition" as used herein refers to a composition suitable for administration to animals, preferably mammals (including humans) comprising at least one active ingredient and at least one inactive ingredient, such as a pharmaceutically acceptable excipient. The preparation of the present invention can be any preparation suitable in the art, such as tablets, capsules, liquid preparations, etc.
[0034] The term "pharmaceutically acceptable excipient" as used herein refers to an ingredient in a pharmaceutical preparation other than the active ingredient, which is non-toxic to an individual. Examples of pharmaceutically acceptable carriers include, but are not limited to, binders, disintegrants, lubricants, solvents, dispersion media, buffers, excipients, antioxidants, preservatives or flavoring agents, etc.
[0035] The term "EED inhibitor" used herein refers to a bioactive agent that can interact with the EED protein directly or indirectly and reduce the signal transduction activity of EED, specifically a group of imidazopyrimidine EED inhibitors with formula (I) described in CN114127073A, more specifically an EED inhibitor compound with formula (III), most preferably the compound of Example 73, or a pharmaceutically acceptable salt or solvate thereof. The entire contents of CN114127073A are incorporated herein by reference.
[0036] As used herein, the term "EED-mediated disease" or "disease that benefits from EED inhibition" refers to a disease or disorder in which EED is involved in its occurrence, the appearance, severity or progression of one or more disease symptoms or markers. Or a disease or disorder in which inhibition of EED will reduce the incidence of the disease, reduce or eliminate the disease symptoms. These diseases or disorders include, but are not limited to, cancer and proliferative diseases, inflammatory diseases, sepsis, autoimmune diseases, and viral infections, the most important of which are cancer and proliferative diseases. A person of ordinary skill in the art can readily determine whether a compound treats a disease or condition of any particular cell type mediated by an EED inhibitor, for example, by an assay that can be conveniently used to assess the activity of a particular compound. See, for example, Yue and Turkson, Expert Opinion Invest Drugs 18:45-56 (2009).
[0037] The terms "patient", "subject", "subject" or "individual" as used herein refer to mammals and non-mammalian individuals in need of the EED inhibitor of the present invention. Examples include, but are not limited to, primates (e.g., humans and non-human primates such as monkeys), horses, cattle, sheep, cats, dogs, rabbits, rabbits, and rodents (e.g., mice and rats), and are not limited to a specific age or sex. In some embodiments, the term is human, including children, adolescents, or adults.
[0038] The term "treatment" as used herein refers to administering the EED inhibitor solid dispersion of the present invention or a pharmaceutical composition comprising the same to an individual with a relevant disease or its symptoms or an individual with a physique susceptible to a relevant disease, in order to cure, alleviate, improve the disease or its symptoms or prevent the individual from suffering from the disease. In a specific embodiment of the present invention, the disease is an EED-mediated disease as defined above, especially a tumor or cancer.
[0039] The term "prevention" as used herein refers to the administration of the EED inhibitor solid dispersion of the present invention or a pharmaceutical composition comprising the same to a subject, such as a mammal, such as a human, suspected of suffering from or susceptible to an EED-mediated disease as defined herein, especially cancer or a tumor, to delay the onset of the disease or reduce the risk of suffering from the disease. The term "prevention" includes the use of the solid dispersion or pharmaceutical composition of the present invention before the diagnosis or determination of any clinical and / or pathological symptoms.
[0040] The term "effective amount" as used herein refers to the amount of a pharmaceutically active agent that is sufficient to prevent one or more symptoms of the disease or disorder being treated or to alleviate the symptoms of the disease to a certain extent when administered alone or in combination with other therapeutic agents to a specific patient or patient population. The effective amount of the EED inhibitor in the solid dispersion or pharmaceutical composition of the present invention is generally about 1 μg / kg to 100 mg / kg / day, for example, a daily dose of about 1 mg / kg to about 10 mg / kg. In some cases, the effective amount of the EED inhibitor of the present invention may be higher than the upper limit of the above dosage range or lower than the lower limit of the above dosage range. Those skilled in the relevant art can determine the effective amount of the EED inhibitor pharmaceutical composition of the present invention by conventional methods (e.g., modeling, dose escalation studies or clinical trials) in combination with conventional influencing factors (e.g., mode of administration, pharmacokinetics of the compound, severity and course of the disease, individual medical history, individual health status, individual response to the drug, etc.).
[0041] The term "AUC" is used herein last " refers to the area under the plasma concentration-time curve from the start of administration to the last point, in ng·h·ml -1 .
[0042] The term "AUC" is used herein INF " refers to the area under the plasma concentration-time curve measured from 0h to infinity, in ng·h·ml -1 .
[0043] The term "C max ” refers to the maximum concentration of the drug in plasma after administration, in ng / ml.
[0044] The term "T" as used hereinmax ” refers to the occurrence of C after administration max The time is in hours (h).
[0045] The term "T" as used herein 1 / 2 ” refers to the time required for the plasma drug concentration to be eliminated by half after the drug distribution in the body reaches equilibrium, and the unit is hour (h).
[0046] Typical acceptable standards for the term "stable" used herein to describe the solid dispersion or oral formulation of the present invention are: the total impurity content measured by the HPLC method described herein does not exceed about 1%, preferably does not exceed about 0.5%, for example, it can be 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%; and / or the physical form of the active ingredient in the solid dispersion / oral formulation remains amorphous, no obvious crystals are present, and no aging occurs when detected by XRPD or DTA or DSC or PLM.
[0047] The expression "based on the weight of the oral preparation" used herein to describe the content of each ingredient means that the content of the active ingredient and other types of excipients are calculated based on the weight of the tablet core excluding the coating agent.
[0048] Any reference to an EED inhibitor appearing herein is intended to include the free compound, as well as a pharmaceutically acceptable salt, hydrate or solvate thereof.
[0049] The term "pharmaceutically acceptable salt" as used herein refers to a salt or zwitterion form of the EED inhibitor compound involved in the present disclosure. The pharmaceutically acceptable salt of the EED inhibitor involved in the present disclosure may be an acid addition salt formed with a pharmaceutically acceptable acid, examples of which include inorganic acids such as nitric acid, boric acid, hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid; and organic acids such as oxalic acid, maleic acid, succinic acid and citric acid. Non-limiting examples of salts of the EED inhibitor involved in the present disclosure include, but are not limited to, hydrochlorides, hydrobromides, hydroiodides, sulfates, bisulfates, 2-hydroxyethanesulfonates, phosphates, hydrogen phosphates, acetates, adipates, alginate, aspartates, benzoates, bisulfates, butyrates, camphorates, camphorsulfonates, digluconates, glycerophosphates, hemisulfates, heptanoates, hexanoates, formates, succinates, fumarates, maleates, ascorbates, Isethionate, salicylate, methanesulfonate, mesitylenesulfonate, naphthalenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, p-toluenesulfonate, undecanoate, lactate, citrate, tartrate, gluconate, methanesulfonate, ethanedisulfonate, benzenesulfonate and p-toluenesulfonate. In addition, available amino groups present in the EED inhibitor compounds of the present disclosure may be quaternized with methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dimethyl, diethyl, dibutyl and diamyl sulfates; decyl, lauryl, myristyl and sterol chlorides, bromides and iodides; and benzyl and phenethyl bromides.
[0050] The term "solvate" as used herein is a combination, physical association and / or dissolution of an EED inhibitor compound of the present disclosure with a solvent molecule, such as a disolvate, a monosolvate or a hemisolvate, wherein the ratio of solvent molecules to the compound of the present disclosure is about 2:1, about 1:1 or about 1:2, respectively. Solvates can generally act as pharmacological equivalents. The EED inhibitor compounds of the present disclosure can exist in a solvated form with a pharmaceutically acceptable solvent such as water, methanol and ethanol. One type of solvate is a hydrate. "Hydrate" refers to a specific subgroup of solvates in which the solvent molecule is water.
[0051] The EED inhibitors contemplated by the present disclosure encompass any disclosed compound that has been isotopically labeled (i.e., radiolabeled) by replacing one or more atoms with atoms having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as 2 H (or deuterium (D)), 3 H. 11C. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl, e.g. 3 H. 11 C and 14 C. In one embodiment, substantially all atoms at a certain position of the EED inhibitor involved in the present disclosure are replaced by atoms having different atomic masses or mass numbers. In another embodiment, substantially all atoms at a certain position of the EED inhibitor involved in the present disclosure are replaced by deuterium atoms, for example, all hydrogen atoms of the -CH3 group are replaced by deuterium atoms to obtain a -CD3 group. In another embodiment, a portion of the atoms at a certain position of the EED inhibitor involved in the present disclosure are replaced by atoms having different atomic masses or mass numbers. In another embodiment, none of the atoms of the EED inhibitor involved in the present disclosure are replaced by atoms having different atomic masses or mass numbers. The isotopically labeled EED inhibitor involved in the present disclosure can be prepared by methods known in the art.
[0052] The EED inhibitors contemplated by the present disclosure may contain one or more asymmetric centers and may therefore give rise to enantiomers, diastereomers and other stereoisomeric forms. The present disclosure encompasses the use of all such possible forms, as well as their racemic and resolved forms and mixtures thereof.
[0053] Technical and scientific terms used herein without specific definition have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. DETAILED DESCRIPTION OF THE INVENTION
[0055] In a first aspect, the present invention provides a solid dispersion comprising an EED inhibitor or a pharmaceutically acceptable salt or solvate thereof and a polymer carrier.
[0056] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the EED inhibitor is the EED inhibitor described in CN114127073A, the entire contents of which are incorporated herein. Specifically, the EED inhibitor involved in the present invention has the following formula:
[0057]
[0058] in:
[0059] R 1 is an aralkyl group;
[0060] R 2Selected from H and C1-C4 alkyl;
[0061] X is selected from -C(R 5a )(R 5b )-, -C(=O)-, and -S(=O)2-; R 5a and R 5b are independently selected from H and C1-C4 alkyl;
[0062] Y is selected from -C(R 6a )(R 6b )-, -S-, -O-, and -N(R 7 );
[0063] Z is -C(R 6c )(R 6d ) m -;
[0064] R 6a and R 6b are independently selected from H and C1-C4 alkyl;
[0065] R 6c and R 6d are each independently selected from H and C1-C4 alkyl; m is 0, 1, or 2;
[0066] R 7 is selected from C1-C6 alkyl, C1-C6 haloalkyl, optionally substituted C3-C8 cycloalkyl;
[0067] L is selected from -C(R 8b )= and -N=;
[0068] R 8a is selected from -CF3, -CH3, -CHF2, -CD3, and cyclopropyl; and
[0069] R 8b and R 8c are hydrogen;
[0070] or a pharmaceutically acceptable salt or solvate thereof.
[0071] In one embodiment, the present invention provides the above solid dispersion, wherein the EED inhibitor is selected from:
[0072]
[0073]
[0074] or a pharmaceutically acceptable salt or solvate thereof.
[0075] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the EED inhibitor is compound A or a pharmaceutically acceptable salt or solvate thereof.
[0076] In one embodiment, the present invention provides the above solid dispersion, wherein the EED inhibitor, such as compound A, can be salified with an acid to obtain a pharmaceutically acceptable salt. The acid is well known to those skilled in the art or can be routinely determined, such as but not limited to hydrochloric acid, methanesulfonic acid, fumaric acid, trifluoroacetic acid or phosphoric acid, sulfuric acid, 2-hydroxyethanesulfonic acid, acetic acid, benzoic acid, succinic acid, maleic acid, oxalic acid, p-toluenesulfonic acid, citric acid, tartaric acid and benzenesulfonic acid.
[0077] In one embodiment, the present invention provides the above solid dispersion, wherein the polymer carrier is selected from cellulose polymers, polyacrylic acid resin polymers or mixtures thereof.
[0078] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the polymer carrier is selected from cellulose esters, such as cellulose acetate, cellulose acetate phthalate; cellulose ethers, such as ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (HPMC); esters of cellulose ethers, such as hydroxypropyl methylcellulose phthalate (HPMCP) and hydroxypropyl methylcellulose acetate succinate (HPMCAS).
[0079] In one embodiment, the present invention provides the above solid dispersion, wherein the polymer carrier is an ester of cellulose ether, such as hypromellose phthalate, such as HP-55, HP-55S and HP-50; and such as hypromellose acetate succinate.
[0080] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the ester polymer carrier of the cellulose ether is preferably hydroxypropyl methylcellulose acetate succinate (HPMCAS), which is a mixture of acetate and succinate of hydroxypropyl methylcellulose, and has amphiphilicity, wherein the acetyl group provides hydrophobicity and the succinyl group provides hydrophilicity. Due to the different contents of acetyl and succinyl groups and the coarseness and fineness of the particles, the HPMCAS that can be used in the solid dispersion of the present invention includes HPMCAS L, HPMCAS LG, HPMCAS M, HPMCAS MG and HPMCAS H, etc. (L, M and H represent gradually increasing acetyl content and gradually decreasing succinyl content, respectively, G represents coarse particle size, and F represents fine particle size), and HPMCAS LG is more preferred.
[0081] In one embodiment, the present invention provides the above solid dispersion, wherein the polymer carrier is a polyacrylic resin polymer selected from methacrylic acid copolymers and methacrylate copolymers.
[0082] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the polymer carrier is selected from the copolymer of butyl methacrylate-dimethylaminoethyl methacrylate-methyl methacrylate; methacrylic acid-ethyl acrylate copolymer; methacrylic acid methyl methacrylate copolymer; ethyl acrylate-methyl methacrylate-methacrylic acid chloride trimethylaminoethyl ester copolymer; ethyl acrylate-methyl methacrylate copolymer; methacrylic acid-methyl acrylate-methyl methacrylate copolymer; methacrylic acid-butyl acrylate copolymer.
[0083] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the polymer carrier is selected from a copolymer of butyl methacrylate-dimethylaminoethyl methacrylate-methyl methacrylate (1:2:1); a methacrylic acid-ethyl acrylate (1:1) copolymer; a methacrylic acid-methyl methacrylate (1:1 or 1:2) copolymer; an ethyl acrylate-methyl methacrylate-trimethylaminoethyl methacrylate chloride (1:2:0.1 or 1:2:0.2) copolymer; an ethyl acrylate-methyl methacrylate (2:1) copolymer; a methacrylic acid-butyl acrylate (35:65) copolymer, and mixtures thereof in any proportion.
[0084] In one embodiment, the present invention provides the above solid dispersion, wherein the polymer carrier is selected from Eudragit. In one embodiment, the present invention provides the above solid dispersion, wherein the polymer carrier is selected from Eudragit E, Eudragit L, Eudragit S, Eudragit RL, Eudragit RS.
[0085] In one embodiment, the present invention provides the above solid dispersion, wherein the polymer carrier is selected from Eudragit E100, Eudragit EPO, Eudragit L100-55, Eudragit L30D-55, Eudragit L100, Eudragit S100, or a mixture thereof in any proportion.
[0086] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the polymer carrier is selected from a copolymer of methacrylic acid-ethyl acrylate (1:1), and / or a copolymer of methacrylic acid-methyl methacrylate (1:1). In one embodiment, the polymer carrier in the solid dispersion of the present invention is Eudragit E100. In one embodiment, the polymer carrier in the solid dispersion of the present invention is Eudragit L100. In one embodiment, the polymer carrier in the solid dispersion of the present invention is Eudragit L100-55.
[0087] In one embodiment, the present invention provides the above solid dispersion, wherein the polymer carrier is a mixture of a cellulose-based polymer and a polyacrylic acid resin-based polymer.
[0088] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the polymer carrier is a mixture of a cellulose polymer and a polyacrylic acid resin polymer, wherein the cellulose polymer is selected from the general or specific cellulose polymers mentioned in the above-mentioned embodiment, preferably esters of cellulose ethers, more preferably hydroxypropyl methylcellulose acetate succinate (HPMCAS), and most preferably HPMCAS LG; wherein the polyacrylic acid resin polymer is selected from the general or specific polyacrylic acid resin polymers mentioned in the above-mentioned embodiment, such as Eudragit, such as Eudragit L100, Eudragit E100, Eudragit L100-55 or a mixture thereof in any proportion, preferably methacrylic acid-ethyl acrylate (1:1) copolymer, such as Eudragit L100-55.
[0089] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the polymer carrier is a mixture of the above-mentioned general or specific cellulose polymer and the above-mentioned general or specific polyacrylic resin polymer, wherein the weight ratio between the cellulose polymer and the polyacrylic resin polymer is about 10:1 to 5:1, for example, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, preferably about 8:1 to 5:1, about 7:1 to 5:1, 7:1 to 6:1, about 6:1 to 5:1, or any integer or non-integer weight ratio therebetween.
[0090] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the weight ratio (drug loading ratio) of the EED inhibitor (e.g., compound A) to the polymer carrier is at least about 1:1, so that a uniform dispersion of the active ingredient and the carrier is obtained by the preparation method of the present invention, so that the active ingredient is completely crystallized and converted into an amorphous form, thereby improving the solubility and absorption of the drug, thereby improving the bioavailability of the drug after oral administration, and the solid dispersion obtained in this way is itself stable, does not show aging phenomenon under accelerated conditions, and there is no obvious change in various indicators. Although the higher the carrier content, the easier it is to dissolve and absorb the active ingredient, the low drug loading rate will increase the quality of the preparation and increase the difficulty of the preparation. After comprehensive consideration, the drug loading ratio in the solid dispersion of the present invention is about 1:1 to 1:5, for example, about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, about 1:5, or any integer or non-integer weight ratio therebetween; preferably about 1:1 to 1:2, about 1:1 to 1:3, about 1:1 to 1:4, about 1:2 to 1:3, about 1:2 to 1:4, about 1:3 to 1:4; more preferably about 1:3 to 1:4.
[0091] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the EED inhibitor (e.g., Compound A) accounts for about 10 to 50% by weight of the solid dispersion, or any integer or non-integer point value therebetween, such as about 5% by weight, 10% by weight, about 15% by weight, about 20% by weight, about 25% by weight, about 30% by weight, about 35% by weight, about 40% by weight, about 45% by weight, about 50% by weight, or any integer or non-integer weight % therebetween.
[0092] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the content of the EED inhibitor (e.g., Compound A) in the solid dispersion is, for example, in the range of about 10-50% by weight, 10-40% by weight, 10-30% by weight, 10-20% by weight, 15-50% by weight, 15-40% by weight, 15-30% by weight, 15-35% by weight, 15-20% by weight, 20-50% by weight, 20-40% by weight, 20-3 %, 20-30% by weight, 25-50% by weight, 25-40% by weight, 25-35% by weight, 25-30% by weight, 30-50% by weight, 30-45% by weight, 30-40% by weight, 30-35% by weight, or any integer or non-integer range value therebetween; preferably about 10-40% by weight, 15-40% by weight, 15-35% by weight, 20-50% by weight, 20-40% by weight, 20-35% by weight.
[0093] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the polymer carrier accounts for about 40% to 90% by weight of the solid dispersion, or any integer or non-integer point value therebetween, such as about 40% by weight, about 45% by weight, about 50% by weight, about 55% by weight, about 60% by weight, about 65% by weight, about 70% by weight, about 75% by weight, about 80% by weight, about 85% by weight, about 90% by weight.
[0094] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the content of the polymer carrier in the solid dispersion is, for example, in the range of about 40-90% by weight, 40-80% by weight, 40-70% by weight, 40-60% by weight, 40-50% by weight, 45-90% by weight, 45-80% by weight, 45-70% by weight, 45-60% by weight, 50-90% by weight, 50-80% by weight, 50-70% by weight, 50-60% by weight. %, 55-90 wt%, 55-80 wt%, 55-70 wt%, 55-65 wt%, 60-90 wt%, 60-80 wt%, 60-70 wt%, 65-90 wt%, 65-80 wt%, 65-75 wt%, 70-90 wt%, 70-80 wt%, or any integer or non-integer point or range therebetween; preferably about 40-80 wt%, 50-80 wt%, 60-80 wt%.
[0095] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the solid dispersion is composed of an EED inhibitor (e.g., compound A) and a polymer carrier, wherein the EED inhibitor is the EED inhibitor generally or preferably described above, most preferably compound A, and the polymer carrier is the polymer carrier generally or preferably described above, more preferably HPMCAS and / or Eudragit (e.g., methacrylic acid-ethyl acrylate (1:1) copolymer, such as Eudragit L100-55), and most preferably HPMCAS LG. In one embodiment, the weight ratio between the EED inhibitor and the polymer carrier constituting the solid dispersion and the weight ratio of each to the solid dispersion are respectively as generally or specifically defined above.
[0096] In one embodiment, the present invention provides the above-mentioned solid dispersion, wherein the content of the EED inhibitor (e.g., compound A) is in the range of 20 to 50% by weight, and the content of the polymer carrier is in the range of 50 to 80% by weight, based on the total weight of the solid dispersion; preferably, the content of the EED inhibitor (e.g., compound A) is in the range of 20 to 40% by weight, and the content of the polymer carrier is in the range of 60 to 80% by weight.
[0097] The solid dispersion provided by the present invention is confirmed by PLM and / or XRPD and / or DSC methods that the active ingredient EED inhibitor (eg compound A) is in an amorphous state and is completely transformed into crystals.
[0098] The above-mentioned solid dispersion provided by the present invention is stable under the following conditions, that is, it has chemical stability and solid stability: high temperature (60°C), high humidity (25°C / RH90%), accelerated conditions (40°C / RH75%), refrigeration (2-8°C), grinding (5-15min / room temperature), grinding and refrigeration (5-15min / 2-8°C), tableting (room temperature or refrigeration), and it is confirmed by PLM and / or XRPD and / or DSC methods that the active ingredient EED inhibitor is in an amorphous state and has no aging phenomenon, and the active ingredient content and impurities do not change significantly.
[0099] The solid dispersion provided by the present invention has a solubility in fasting simulated intestinal fluid (FaSSIF) at pH 6.5 that can remain stable for at least 24 hours, and its solubility is at least about 10 times, for example, about 10 times, about 20 times, about 25 times, about 30 times, about 35 times, about 40 times, about 50 times, or about 60 times that of the original EED inhibitor (e.g., compound A) under the same conditions.
[0100] In one embodiment, the present invention provides the above-mentioned solid dispersion, which comprises an EED inhibitor (e.g., Compound A) and a polymer carrier cellulose ether ester (e.g., HPMCAS) and a polyacrylic acid resin (e.g., Eudragit, e.g., methacrylic acid-ethyl acrylate (1:1) copolymer, e.g., Eudragit L100-55), wherein the EED inhibitor, its drug loading, the cellulose ether ester and polyacrylic acid resin polymer carriers and their contents and the weight ratio between the two are generally and specifically defined above for the corresponding characteristics, and the solubility of the solid dispersion in fed state simulated intestinal fluid (FeSSIF) at pH 5.8 remains stable for at least 24 hours, and the EED inhibitor remains free of crystallization for at least 24 hours.
[0101] In one embodiment, the EED inhibitor (e.g., compound A) and a cellulose ether ester polymer carrier (e.g., HPMCAS) can be first prepared into a solid dispersion according to the method of the present invention, and then a polyacrylic resin (e.g., Eudragit, e.g., methacrylic acid-ethyl acrylate (1:1) copolymer, e.g., Eudragit L100-55) polymer can be added. The mixture containing the solid dispersion prepared in this way can also make the active ingredient EED inhibitor in an amorphous state, have the above-mentioned chemical stability and solid stability, and its solubility in fasting state simulated intestinal fluid (FaSSIF) at pH 6.5 can remain stable for at least 24 hours and is much higher than the solubility of the EED inhibitor original drug under the same conditions, and its solubility in fed state simulated intestinal fluid (FeSSIF) at pH 5.8 remains stable for at least 24 hours and remains without crystallization for at least 24 hours.
[0102] The solid dispersion provided by the present invention shows in animal pharmacokinetic experiments (such as the beagle dog pharmacokinetic study shown in the examples) that when administered at the same dose, the in vivo exposure of the EED inhibitor solid dispersion of the present invention is equivalent to that of the EED inhibitor solution, and the AUC value reaches at least 80% of that of the solution.
[0103] The solid dispersion provided by the present invention can be used directly, or prepared into different dosage forms according to the needs of treatment or prevention.
[0104] In a second aspect, the present invention provides a method for preparing the solid dispersion of the EED inhibitor of the present invention. The solid dispersion of the present invention can be obtained by widely known preparation methods, such as melting method, solvent method, solvent-melting method, spray drying method, fluidized bed drying method, melt extrusion method, etc.
[0105] In a specific embodiment, the present invention preferably prepares the EED inhibitor solid dispersion by a spray drying method, which comprises the following steps:
[0106] (1) dissolving an EED inhibitor (e.g., compound A) in an organic solvent, then adding a polymer carrier, stirring and dissolving the mixture, and preparing a spray drying solution;
[0107] (2) spray drying the solution obtained in step (1) to remove the organic solvent.
[0108] In one embodiment, the method for preparing a solid dispersion of an EED inhibitor further comprises step (3): drying the spray-dried powder obtained in step (2) under reduced pressure.
[0109] In step (1), there is no strict limitation on the organic solvent used, but it should be able to fully dissolve the EED inhibitor, such as but not limited to methanol, anhydrous ethanol, isopropanol, isobutanol, ethyl acetate, acetone, dichloromethane, n-hexane, n-heptane, tetrahydrofuran, acetonitrile, benzene, toluene, xylene, dimethyl sulfoxide, dimethylformamide, N,N-dimethylacetamide; preferably dichloromethane, methanol or a mixture thereof in any proportion; more preferably a dichloromethane / methanol mixed solvent of about 2:1 to 3:1.
[0110] In step (1), the amount of organic solvent used should be an amount that can fully dissolve the EED inhibitor; the solid content concentration of the suitable solution is not more than 120 mg / mL, preferably in the range of 20-80 mg / mL, and more preferably in the range of 40-60 mg / mL.
[0111] In step (1), there is no strict limitation on the form of the EED inhibitor, and either an amorphous form or a crystalline form can be used. EED inhibitors in different crystalline forms can be converted into an amorphous form in the solid dispersion system of the present invention.
[0112] In step (2), there is no strict restriction on the conditions and means of drying, as long as the organic solvent can be removed. In one embodiment, the drying in step (2) is carried out by spray drying. Those skilled in the art can determine the various parameters of spray drying, for example, the air inlet temperature of spray drying can be controlled within the range of 65 to 95° C., for example, at 70° C. In a specific embodiment, spray drying is carried out under light-proof conditions.
[0113] In one embodiment, after step (2), the reduced pressure drying of step (3) is optionally performed to further remove the organic solvent; the conditions of the reduced pressure drying are not strictly limited and can be determined by those skilled in the art. In a specific embodiment, the reduced pressure drying is performed at a temperature of 25 to 50° C. (e.g., 50° C.) and a reduced pressure of 0 to -0.1 MPa (e.g., -0.1 MPa) for a suitable time, such as but not limited to 2 to 5 hours, such as 4 hours.
[0114] In the method for preparing a solid dispersion according to this aspect of the invention, the yield of the solid dispersion reaches at least 75% and has good compressibility.
[0115] In a third aspect, the present invention provides a solid dispersion composition comprising a solid dispersion of the present invention and an excipient, wherein the solid dispersion is as generally or specifically defined herein for the solid dispersion of the present invention, and wherein the excipient is selected from one or more of a diluent, a flavoring agent, a surfactant, a filler, a binder, a disintegrant, a lubricant, a glidant / antiadherent, a stabilizer, an emulsifier, a coating agent and / or a release modifier.
[0116] In one embodiment, the present invention provides a solid dispersion composition, which can be in the form of tablets, capsules, granules, powders or pills.
[0117] In a fourth aspect, the present invention provides a method for preparing the solid dispersion composition of the present invention, comprising the following steps:
[0118] (1) uniformly mixing the EED inhibitor solid dispersion of the present invention with a filler, a binder, a disintegrant, a stabilizer and / or a glidant;
[0119] (2) optionally granulating the mixture of step (1);
[0120] (3) Optionally, the granules obtained in step (2) are thoroughly mixed with a lubricant.
[0121] In one embodiment, the composition prepared above can be prepared in the form of pills, granules, powders, etc., or can be further compressed into tablets, or the obtained mixture or granules can be directly filled into capsule shells to prepare capsules.
[0122] In a fifth aspect, the present invention provides an oral formulation of an EED inhibitor (eg, Compound A), comprising the solid dispersion of the present invention or the solid dispersion composition of the present invention, and optionally an excipient.
[0123] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (eg, Compound A), which is a solid oral formulation selected from tablets, capsules, granules, powders, lozenges and pills, preferably tablets or capsules, more preferably tablets.
[0124] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (eg, Compound A) comprising a solid dispersion of the present invention and one or more of a filler, a stabilizer, a binder, a disintegrant, a lubricant, a glidant, and a coating agent.
[0125] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (eg, Compound A) comprising the solid dispersion of the present invention, and further comprising a filler, a binder, a disintegrant, and a lubricant.
[0126] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (eg, Compound A) comprising a solid dispersion of the present invention, and further comprising a filler, a binder, a disintegrant, a lubricant, and a glidant.
[0127] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (eg, Compound A) comprising a solid dispersion of the present invention, and further comprising a filler, a binder, a disintegrant, a lubricant, a stabilizer, and a glidant.
[0128] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (eg, Compound A) comprising a solid dispersion of the present invention, and further comprising a filler, a binder, a disintegrant, a lubricant, a stabilizer, a glidant, and a coating agent.
[0129] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (e.g., Compound A), wherein the content of the EED inhibitor is about 5-40% by weight, or any integer or non-integer point or range value therebetween, such as but not limited to about 5-30% by weight, about 5-20% by weight, about 10-40% by weight, about 10-30% by weight, about 10-20% by weight, about 15-40% by weight, about 15-30% by weight, about 15-25% by weight, about 20-40% by weight, about 20-30% by weight, about 25-40% by weight, about 25-35% by weight, about 30-40% by weight, preferably about 10-30%, more preferably about 10-20%, based on the weight of the oral formulation.
[0130] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (e.g., Compound A), wherein the amount of the EED inhibitor in a unit preparation is about 5-500 mg, for example, but not limited to, about 5-400 mg, about 5-300 mg, about 5-200 mg, about 10-500 mg, about 10-400 mg, about 10-200 mg, preferably about 10-200 mg, for example, about 200 mg, about 150 mg, about 100 mg, about 75 mg, about 50 mg, about 25 mg, about 15 mg, about 10 mg, more preferably about 10 mg, about 50 mg, about 200 mg.
[0131] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (e.g., Compound A), wherein the solid dispersion accounts for about 10-80% by weight of the oral formulation, or any integer or non-integer point or range value therebetween, such as but not limited to about 10-70%, about 10-50%, about 20-80%, about 20-70%, about 20-60%, about 30-80%, about 30-70%, about 30-50%, about 40-80%, about 40-70%, about 50-80%, about 50-70%, preferably about 30-80%, about 40-80%, about 40-70%, about 50-80%, about 50-70%, preferably about 30-80%, about 40-80%, about 40-70%, about 50-80%, about 50-70%, and more preferably about 50-70%.
[0132] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (e.g., Compound A), wherein the filler can be selected from lactose, sucrose, calcium phosphate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, microcrystalline cellulose, silicified microcrystalline cellulose, pregelatinized starch, starch, mannitol, etc.; preferably, the filler is microcrystalline cellulose; the amount of the filler accounts for about 10-80% by weight of the oral formulation, or any integer or non-integer point value or range value therebetween, such as but not limited to about 10-70%, about 10-60%, about 10 ~50%, about 10~40%, about 10~30%, about 15~35%, about 15~40%, about 20~80%, about 20~70%, about 20~60%, about 20~50%, about 20~40%, about 30~80%, about 30~70%, about 30~60%, about 30~50%, about 30~40%, preferably about 10~60%, about 15~40%, about 20~60%, about 20~40%, about 20~30%, more preferably about 20~40%, and most preferably about 20~30%.
[0133] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (e.g., Compound A), wherein the binder can be selected from polyvinyl pyrrolidone, starch, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, alginate, etc.; preferably, the binder is selected from polyvinyl pyrrolidone or hydroxypropyl methylcellulose; the amount of the binder is 0.5-10% by weight of the oral formulation, or any integer or non-integer point value or range value therebetween, such as but not limited to about 0.5-9%, about 0.5-8%, about 0.5-5%, about 1-10%, about 1-9%, about 1-8%, about 1-5%, about 1-3%, about 1.5-2.5%, about 2-10%, about 2-8%, about 2-5%, about 2-4%, preferably about 0.5-5%, about 1-3%, about 1.5-2.5%, more preferably about 1-3%, and most preferably about 1.5-2.5%.
[0134] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (e.g., Compound A), wherein the disintegrant can be selected from cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, starch, pregelatinized starch, etc.; preferably, the disintegrant is cross-linked sodium carboxymethyl cellulose; the amount of the disintegrant is 1-20% by weight of the oral formulation, or any integer or non-integer point value or range value therebetween, such as but not limited to about 1.0%, about 2.0%, about 5.0%, about 7.0%, about 10%, about 15%, about 20%, about 1-10%, about 1-8%, about 2-10%, about 2-8%, about 2-7%, about 3-10%, about 3-8%, about 3-7%, about 4-10%, about 4-8%, preferably about 1-10%, about 2-8%, about 3-7%, more preferably about 2-8%, and most preferably about 3-7%.
[0135] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (e.g., Compound A), wherein the lubricant can be selected from stearic acid, magnesium stearate, calcium stearate, zinc stearate, palmitic acid, palmitostearylglycerol, talc, carnauba wax, sodium lauryl sulfate, sodium stearyl fumarate, etc.; preferably, the lubricant is selected from stearic acid, magnesium stearate, calcium stearate and zinc stearate; the amount of the lubricant is 0.1-5% by weight of the oral formulation, or any integer or non-integer point value or range value therebetween, such as but not limited to about 0.1%, about 0.5%, about 1.0% , about 1.5%, about 2.0%, about 2.5%, about 3.0%, about 3.5%, about 4.0%, about 4.5%, about 5.0%, about 0.5-5%, about 0.5-4%, about 0.5-3%, about 0.5-2%, about 0.5-2.5%, about 0.5-1.5%, about 1-5%, about 1-4%, about 1-3%, about 1-2.5%, about 1-2%, preferably about 0.5-3%, about 0.5-2%, about 0.5-1.5%, about 1-3%, about 1-2%, more preferably about 0.5-2%, and most preferably about 0.5-1.5%.
[0136] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (e.g., Compound A), which further comprises a stabilizer, wherein the stabilizer can be selected from hydroxypropyl methylcellulose, sodium lauryl sulfate, polyacrylic acid resin polymers, etc., preferably polyacrylic acid resin polymers, such as the general or specific polyacrylic acid resin polymers mentioned in the above embodiments, such as Eudragit, such as Eudragit L100, Eudragit E100, Eudragit L100-55 or a mixture thereof in any proportion, preferably methacrylic acid-ethyl acrylate (1:1) copolymer such as Eudragit L100-55; the amount of the stabilizer accounts for 1 to 20% by weight of the oral formulation, or any integer or non-integer point value or range value therebetween, for example but not limited to about 1.0%, about 2.0%, about 3.0%, about 5.0%, about 7.0%, about 10%, about 12%, about 15%, about 1 to 10%, about 1 to 8%, about 2 to 10%, about 2 to 8%, about 3 to 10%, about 3 to 8%, about 4 to 10%, about 4 to 8%, about 5 to 10%, about 5 to 8%, preferably about 1 to 10%, about 5 to 10%, about 2 to 8%, about 4 to 8%, more preferably about 2 to 8%, and most preferably about 4 to 8%.
[0137] In one embodiment, the present invention provides an oral formulation of an EED inhibitor (e.g., Compound A), which further comprises a glidant, which can be selected from talc, silicon dioxide, micropowdered silica (colloidal silicon dioxide) and other pharmaceutically acceptable forms of silicon dioxide; preferably, the glidant is colloidal silicon dioxide; the amount of the glidant is 0 to 5% by weight of the oral formulation, or any integer or non-integer point value or range value therebetween, such as but not limited to 0%, about 0%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 7 .5%, about 1.0%, about 1.5%, about 2.0%, about 2.5%, about 3.0%, about 3.5%, about 4.0%, about 4.5%, about 0.5-5%, 0.5-4%, 0.5-3%, 0.5-2%, 0.5-1.5%, 1-3%, 1-2%, preferably about 0.5-4%, 0.5-3%, 0.5-2%, 0.5-1.5%, more preferably about 0.5-2%, and most preferably about 0.5-1.5%.
[0138] In one embodiment, the present invention provides an oral formulation of the above-mentioned EED inhibitor (eg, Compound A), such as a tablet, comprising:
[0139] 1) about 10-80% by weight of a solid dispersion as generally or specifically defined herein, comprising about 5-500 mg of an EED inhibitor as generally or specifically defined herein (e.g., Compound A), and a polymer carrier as generally or specifically defined herein;
[0140] 2) about 10 to 80 weight percent of a filler as generally or specifically defined herein;
[0141] 3) about 0.5 to 10 weight percent of a binder as generally or specifically defined herein;
[0142] 4) about 1 to 20% by weight of a disintegrant as generally or specifically defined herein; and
[0143] 5) about 0.1 to 5 weight percent of a lubricant as generally or specifically defined herein;
[0144] Preferably comprising:
[0145] 1) about 50-80% by weight of a solid dispersion as generally or specifically defined herein, comprising about 10-500 mg of an EED inhibitor as generally or specifically defined herein (e.g., Compound A), and a polymer carrier as generally or specifically defined herein;
[0146] 2) about 20 to 60 weight percent of a filler as generally or specifically defined herein;
[0147] 3) about 0.5 to 5 weight percent of a binder as generally or specifically defined herein;
[0148] 4) about 1 to 10% by weight of a disintegrant as generally or specifically defined herein; and
[0149] 5) about 0.5 to 3 weight percent of a lubricant as generally or specifically defined herein;
[0150] More preferably, it comprises:
[0151] 1) about 30-80% by weight of a solid dispersion as generally or specifically defined herein, comprising about 10-200 mg of an EED inhibitor as generally or specifically defined herein (e.g., Compound A), and a polymer carrier as generally or specifically defined herein;
[0152] 2) about 20 to 40 weight percent of a filler as generally or specifically defined herein;
[0153] 3) about 1 to 3 weight percent of a binder as generally or specifically defined herein;
[0154] 4) about 2 to 8 weight percent of a disintegrant as generally or specifically defined herein; and
[0155] 5) about 0.5 to 2 weight percent of a lubricant as generally or specifically defined herein;
[0156] Most preferably comprises:
[0157] 1) about 50-70% by weight of a solid dispersion as generally or specifically defined herein, comprising about 10-200 mg of an EED inhibitor as generally or specifically defined herein (e.g., Compound A), and a polymer carrier as generally or specifically defined herein;
[0158] 2) about 20 to 30 weight percent of a filler as generally or specifically defined herein;
[0159] 3) about 1.5 to 2.5 weight percent of a binder as generally or specifically defined herein;
[0160] 4) about 3 to 7 weight percent of a disintegrant as generally or specifically defined herein; and
[0161] 5) about 0.5 to 1.5 weight percent of a lubricant as generally or specifically defined herein;
[0162] The above general, preferred, more preferred or most preferred oral formulations further optionally contain:
[0163] 6) about 1 to 20 wt. %, preferably about 1 to 10 wt. %, more preferably about 2 to 8 wt. %, most preferably about 4 to 8 wt. % of a stabilizer as generally or specifically defined herein; and / or
[0164] The above general, preferred, more preferred or most preferred oral formulations further optionally contain:
[0165] 7) about 0-5 wt%, preferably about 0.5-3 wt%, more preferably about 0.5-2 wt%, most preferably about 0.5-1.5 wt% of a glidant as generally or specifically defined herein.
[0166] It should be noted that in the oral preparations of the EED inhibitor of the present invention (e.g., compound A) generally or preferably defined above, the solid dispersion, the selection of its components, the content of each component and the ratio between them (e.g., drug loading ratio, ratio between polymer carriers) are all as defined in the first aspect of the present invention above, that is, the solid dispersion technical solution constituted by the general or preferred definition of each technical feature, and also the solid dispersion technical solution constituted by any combination of one or preferred definitions of each technical feature.
[0167] In one embodiment, the present invention provides an oral formulation of the above-mentioned EED inhibitor, such as a tablet, wherein the EED inhibitor is Compound A or a pharmaceutically acceptable salt or solvate thereof, and the polymer carrier in the solid dispersion is hydroxypropyl methylcellulose acetate succinate (HPMCAS).
[0168] In one embodiment, the present invention provides an oral formulation of the above-mentioned EED inhibitor, such as a tablet, wherein the EED inhibitor is compound A or a pharmaceutically acceptable salt or solvate thereof, and the polymer carrier in the solid dispersion is a mixture of cellulose ether esters (such as HPMCAS) and polyacrylic acid resins (such as Eudragit, such as methacrylic acid-ethyl acrylate (1:1) copolymer, such as Eudragit L100-55) polymers generally or specifically defined herein.
[0169] In one embodiment, the present invention provides an oral formulation of the above-mentioned EED inhibitor, such as a tablet, wherein the EED inhibitor is compound A or a pharmaceutically acceptable salt or solvate thereof, and the polymer carrier in the solid dispersion is a polyacrylic acid resin (e.g., Eudragit, such as methacrylic acid-ethyl acrylate (1:1) copolymer, such as Eudragit L100-55) polymer generally or specifically defined herein.
[0170] In one embodiment, the present invention provides an oral formulation of the above-mentioned EED inhibitor (e.g., Compound A), such as a tablet, wherein the filler is microcrystalline cellulose, the binder is hypromellose, the disintegrant is cross-linked sodium carboxymethyl cellulose, the lubricant is magnesium stearate, the stabilizer is methacrylic acid-ethyl acrylate (1:1) copolymer (e.g., Eudragit L100-55), and the glidant is colloidal silicon dioxide.
[0171] In one embodiment, the present invention provides an oral formulation of the above-mentioned EED inhibitor (e.g., Compound A), such as a tablet, wherein the tablet can be a coated tablet, wherein the coating agent is well known to those skilled in the art, such as but not limited to sodium carboxymethylcellulose, cellulose acetate, cellulose acetate phthalate, methylcellulose, ethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, methacrylic acid copolymer, gelatin, pharmaceutical glaze, polyethylene glycol, polyvinyl acetate phthalate, sodium lauryl sulfate, shellac, sucrose, titanium dioxide, carnauba wax, corn alcohol soluble protein, Opadry, etc. or a mixture thereof, or a conventional film coating premix well known to those skilled in the art; the amount of the coating agent is 0-10% by weight of the oral formulation, or any range therebetween, for example but not limited to about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.5%, about 2.0%, about 2.5%, about 3.0%, about 3.5%, about 4.0%, about 4.5%, about 5.0%, about 6.0%, about 7.0%, about 8.0%, about 9.0%, about 10%, preferably about 1-5%, 2-4%, more preferably about 2-4%, based on the weight of the oral formulation.
[0172] The oral preparations of the above-mentioned EED inhibitor (e.g., compound A) provided by the present invention, such as tablets, dissolve rapidly and completely. Under the conditions of 0.15% sodium dodecyl sulfate (SDS) aqueous medium at pH 6 to 7, the solubility of the active ingredient is maintained at about 75% or higher, preferably about 80% or higher, more preferably 85% or higher, at 30 minutes; and maintained at about 85% or higher, preferably about 90% or higher, at 45 minutes.
[0173] The oral preparation of the above-mentioned EED inhibitor (e.g., compound A) provided by the present invention is a tablet, and the tablet hardness is between about 50 and 400 N. In a specific embodiment, for a 10 mg tablet, the hardness is between about 30 and 90 N, preferably between about 30 and 80 N. In a specific embodiment, for a 50 mg tablet, the hardness is between about 50 and 200 N, preferably between about 70 and 150 N. In a specific embodiment, for a 200 mg tablet, the hardness is between about 150 and 400 N, preferably between about 200 and 360 N.
[0174] The oral preparation of the above-mentioned EED inhibitor (such as compound A) provided by the present invention is a tablet, and its tablet friability is less than about 1% by weight, preferably less than about 0.5% by weight, such as less than about 0.2% by weight, and more preferably less than about 0.1% by weight.
[0175] The oral preparation of the EED inhibitor (eg, compound A) provided by the present invention is a tablet having a disintegration time of less than about 15 minutes, preferably less than about 5 minutes, such as about 0.5 to 5 minutes.
[0176] The oral preparation of the above-mentioned EED inhibitor (such as compound A) provided by the present invention has a mixture of raw materials and excipients with good stability. When placed under high temperature (60°C), high humidity (25°C / RH90%±5%), accelerated (40°C±2°C / RH75%±5%) and light-proof conditions for 0 / 5 / 10 / 30 days, there is no obvious change in appearance and no obvious increase in related substances.
[0177] The oral preparation of the above-mentioned EED inhibitor (e.g., compound A) provided by the present invention is a tablet. The finished preparation after being packaged with conventional packaging materials has good stability. After being placed under 40°C±2°C / RH75%±5%, 30°C±2°C / RH65%±5% and 25°C±2°C / RH60%±5% conditions for 1 month, the appearance, moisture, related substances, content and solubility of the tested samples did not change significantly.
[0178] In a sixth aspect, the present invention provides a method for preparing the oral preparation in the form of a tablet of the present invention, comprising the following steps:
[0179] (1) uniformly mixing the EED inhibitor solid dispersion of the present invention, a filler, a binder, a disintegrant, a stabilizer and / or a glidant in a mixer;
[0180] (2) granulating the mixture of step (1);
[0181] (3) fully mixing the particles obtained in step (2) with a lubricant;
[0182] (4) tableting the mixture obtained in step (3).
[0183] In a preferred embodiment, in step (1), the EED inhibitor solid dispersion of the present invention, a filler, a stabilizer, a binder, a disintegrant and a glidant are uniformly mixed.
[0184] In a preferred embodiment, the mixture of step (1) is sieved before mixing.
[0185] In a preferred embodiment, the screened mixture of step (1) is mixed again.
[0186] In a preferred embodiment, before the granulation of step (2), the mixture of step (1) is fully mixed with a portion of lubricant; the portion of lubricant added may be suitably about 40-70% of the total weight of the lubricant in the formulation, preferably about 50-70%. Adding a portion of lubricant at this stage helps to further improve the adhesion phenomenon in the subsequent granulation process and the sticking phenomenon in the tableting process.
[0187] In step (2), there is no strict limitation on the conditions and means of granulation, and the granulation may be wet granulation, dry granulation or melt granulation.
[0188] In a preferred embodiment, the granulation in step (2) is performed by dry granulation, which can be performed by conventional methods known in the art, such as roller compaction. For example, see "Pharmaceutics", edited by Fang Liang, third edition, July 2015, China Medical Science and Technology Press.
[0189] In a preferred embodiment, the pressure of dry granulation can be 6-8 KPa, preferably 4-6 KPa. Adopting the pressure range can further reduce the adhesion of dry granulated materials on the roller, further improve the fluidity of the prepared granules, and further reduce the sticking phenomenon during tableting.
[0190] The tablets prepared according to the above method have a friability of less than 1%, preferably less than about 0.5%; a disintegration time of less than 15 minutes, preferably less than 10 minutes, less than 5 minutes; and a solubility in an SDS solution of pH 6.8 of more than 75% in 30 minutes and more than 85% in 45 minutes.
[0191] In one embodiment, the method for preparing an oral preparation in tablet form according to this aspect of the invention further comprises step (5): coating the tablet prepared in step (4) with a coating material.
[0192] In step (5), there is no particular limitation on the coating material used, but it should have no significant effect on the content and dissolution of the tablets and play a light-shielding role to further improve the storage stability of the tablet preparation.
[0193] In one embodiment, the coating material of step (5) accounts for about 1-5%, preferably 2-4%, of the total weight of the oral tablet formulation, and adds about 1-5%, preferably 2-4% to the weight of the tablet core.
[0194] It should be noted that in the preparation methods of the second aspect, the fourth aspect and the sixth aspect of the present invention, the selection and dosage of the EED inhibitor (e.g., compound A), the polymer carrier, the solid dispersion, and various excipients are as generally, specifically or preferably defined above for the corresponding technical scheme. Most preferably, the EED inhibitor is compound A or a pharmaceutically acceptable salt or solvate thereof, the polymer carrier is hydroxypropyl methylcellulose acetate succinate (HPMCAS) and / or methacrylic acid-ethyl acrylate (1:1) copolymer (e.g., Eudragit L100-55), the filler is microcrystalline cellulose, the stabilizer is methacrylic acid-ethyl acrylate (1:1) copolymer (e.g., Eudragit L100-55), the binder is hypromellose, the disintegrant is cross-linked sodium carboxymethyl cellulose, the lubricant is magnesium stearate, and the glidant is colloidal silicon dioxide.
[0195] In a seventh aspect, the present invention provides use of the above-mentioned solid dispersion, solid dispersion composition or oral formulation of the present invention for treating or preventing a disease (eg, cancer or tumor) for which inhibition of EED provides benefits.
[0196] In an eighth aspect, the present invention provides use of the above-mentioned solid dispersion, solid dispersion composition or oral formulation of the present invention in the preparation of a medicament for treating or preventing a disease (eg, cancer or tumor) for which inhibition of EED provides benefits.
[0197] In a ninth aspect, the present invention provides a method for treating or preventing a disease (e.g., cancer or tumor) in a patient for which inhibition of EED provides benefits, comprising administering a therapeutically effective amount of a solid dispersion, solid dispersion composition, or oral formulation of the present invention to a subject in need thereof.
[0198] It should be noted that the "diseases that benefit from EED inhibition" described in the seventh to ninth aspects of the present invention are selected from cancer and proliferative diseases, inflammatory diseases, sepsis, autoimmune diseases and viral infections, preferably cancer and proliferative diseases. For specific examples, please refer to the corresponding content of CN114127073A.
[0199] In one embodiment, the "disease that benefits from EED inhibition" described in the seventh to ninth aspects of the present invention is cancer, selected from acute monocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, mixed lineage leukemia, NUT-midline carcinoma, multiple myeloma, small cell lung cancer, non-small cell lung cancer, neuroblastoma, Burkitt's lymphoma, cervical cancer, esophageal cancer, ovarian cancer, colorectal cancer, prostate cancer, breast cancer, bladder cancer, ovarian cancer, glioma, sarcoma, esophageal squamous cell carcinoma and papillary thyroid carcinoma.
[0200] The various technical solutions of the present invention described above prepare the EED inhibitor active ingredient, such as compound A, which is poorly soluble in water into a solid dispersion using a specific type of polymer carrier, and the active drug ingredient maintains a stable invisible state in the solid dispersion environment, while improving the dissolution and solubility of the drug in the gastrointestinal fluid, thereby improving the oral bioavailability of the drug. The tablets prepared using the solid dispersion and a specific excipient combination have good preparation properties, and the friability, hardness, disintegration time and solubility have reached excellent levels at the same time. The preparation method adopted is simple in process, the parameters are easy to control, the reproducibility is good, and it is easy to industrialize production. BRIEF DESCRIPTION OF THE DRAWINGS
[0201] Figure 1A , Figure 1B and Figure 1C Shown are the DSC spectra of compound A (hereinafter also referred to as API), a representative polymer carrier, and a mixture of compound A and a representative polymer carrier (drug loading ratio 1:3).
[0202] Figure 2 PLM photographs showing solid dispersions prepared with different carriers (hydroxypropyl methylcellulose acetate succinate-LG, copovidone VA64 or hydroxypropylcellulose EXF) and API.
[0203] Figure 3A The XRPD patterns of solid dispersions prepared with different carriers (hydroxypropyl methylcellulose acetate succinate-LG, copovidone VA64 or hydroxypropyl cellulose EXF) and API are shown; Figure 3B The XRPD patterns of solid dispersions prepared with different carriers (Eutrac L100-55 or Eudragit L100-55+HPMCAS-LG) and API are shown; Figure 3C The XRPD patterns of solid dispersions with different drug loading ratios (API:HPMCAS-LG) are shown.
[0204] Figure 4A-4D DSC spectra of solid dispersions with different drug loading ratios (API:HPMCAS-LG) are shown.
[0205] Figure 5A The dynamic solubility of compound A solid dispersions prepared with different polymer carriers in FaSSIF-V2 solution is shown; Figure 5B The dynamic solubility of solid dispersions with different drug loading ratios (API:HPMCAS-LG) in FeSSIF-V2 solution is shown when Eudragit L100-55 is additionally added.
[0206] Figure 6 The pharmacokinetic properties of the solid dispersion of the present invention are shown in beagle dogs following oral administration.
[0207] Figure 7 The dissolution properties of the solid oral preparation of the present invention are shown. DETAILED DESCRIPTION
[0208] The present invention is further described and explained by the following examples, but they do not constitute limitations on the scope of the present invention.
[0209] Unless otherwise specified, the excipients and reagents used in the examples are from commercial sources, and their quality standards and dosages are in compliance with the standards of the Chinese Pharmacopoeia; the EED inhibitor used in the present invention can be prepared by referring to the method described in CN114127073A, for example, compound A or a pharmaceutically acceptable salt thereof can be prepared by referring to the method of Example 73 therein.
[0210] General experimental methods
[0211] 1. X-ray powder diffraction (XRPD): D8 Advance instrument equipped with Lynxeye detector was used to analyze the X-ray (Cu, Kα The spectra were recorded under the conditions of 1.54), 45 kV / 40 mA, step size (°2θ) 0.02, scan rate (s / step) 0.1, and scan range (°2θ) 3-40.
[0212] 2. Polarized light microscope (PLM): Using Axiolab5 instrument, at room temperature, take an appropriate amount of the sample to be tested on a slide, add a small amount of paraffin to disperse the sample, cover the sample with a cover glass to disperse the sample, then remove the cover glass and observe under a 20x objective lens (magnification 200x).
[0213] 3. Modulated differential scanning calorimetry (mDSC): using Discovery DSC 2500, linear temperature increase (10°C / min), the spectrum was recorded from 25°C under nitrogen.
[0214] 4. Determination of active ingredient content: A high performance liquid chromatography (HPLC) equipped with a UV detector or a diode array detector and an autosampler was used, the chromatographic column was Waters Xbridge C18 (4.6×150 mm, 3.5 μm, column temperature 30°C), the mobile phase was (A:B=40:60, A: 0.05% phosphoric acid aqueous solution, B: 0.05% phosphoric acid solution in methanol:acetonitrile (1:9)), the flow rate was 0.8 mL / min, the sample was diluted with methanol, 10 μL was injected, and the change of the absorbance at UV 249 nm over time was recorded.
[0215] 5. Determination of dissolution, tablet friability, hardness and disintegration time: carried out according to conventional methods in the art, for example, with reference to the corresponding determination methods in the Chinese Pharmacopoeia 2015 edition.
[0216] 6. Fasting state simulated intestinal fluid (FaSSIF), fed state simulated intestinal fluid (FeSSIF) and gastric simulated fluid (SGF) can use commercially available products, or be prepared in the following manner:
[0217] Preparation of FaSSIF-V2 solution: weigh 1.39 g of sodium hydroxide, 2.22 g of maleic acid, and 4.01 g of sodium chloride, dilute to 1000 ml, dissolve by ultrasonication, adjust the pH to 6.5 for later use, add 1.79 g of FaSSIF-V2 powder, dissolve and set aside.
[0218] Preparation of FeSSIF-V2 solution: weigh 1.64 g of sodium hydroxide, 3.19 g of maleic acid, and 3.67 g of sodium chloride, dissolve them in 500 ml of pure water, adjust the pH to pH 5.8, add 4.88 g of FeSSIF-V2 solution, sonicate until all dissolved, and set aside.
[0219] Preparation of gastric simulation solution (SGF): Take 0.96 ml of concentrated hydrochloric acid, add 150 ml of water and 2.5 g of pepsin, shake well, and dilute with water to 250 ml for use.
[0220] 7. Preparation of solid dispersion: Weigh the prescribed amount of compound A, add a solvent (e.g., a mixed solvent of dichloromethane and methanol), stir until dissolved, add the prescribed amount of carrier material, stir to dissolve, place in a spray dryer, select appropriate parameters such as inlet temperature, inlet volume, liquid inlet speed and pressure for spray drying, and obtain the solid dispersion of the present invention. Spray drying equipment suitable for the present invention includes but is not limited to corresponding equipment produced by Niro GEA Process Engineering Inc., BuchiLabortechnik AG., ProCept and SPX ANHYDROUS. The present invention exemplarily uses a BUCHI290 spray dryer within the following parameter range:
[0221] Process parameters Setting Value Inlet Temp 65-95℃ Q-Flow 20~30mm Outlet Temp 40~70℃ Pump 15%~20% Cooling Temp -2℃ Nozzle Cleaner 2
[0222] The powder obtained by the spray drying can also be further subjected to secondary drying, such as reduced pressure drying, for example, at a temperature of 25 to 50° C. (e.g. 50° C.) and a reduced pressure of 0 to -0.1 MPa (e.g. -0.1 MPa) for a suitable time, such as 2-5 hours, such as 4 hours.
[0223] Example 1
[0224] The solubility of active ingredient compound A in various solvents (25° C.) was determined using a standard solubility determination method known in the art. The results are shown in Table 1 below:
[0225] Table 1
[0226]
[0227]
[0228] Based on the above experimental results, taking into account factors such as economy, dissolution efficiency and toxicity, the present invention adopts a mixed solvent of dichloromethane and methanol as the solvent system for preparing the solid dispersion.
[0229] Example 2
[0230] Weigh 12 mg of various carrier substances and place them in a 2 ml liquid phase vial with 8 mg of compound A free base crystals, then add 1 ml of solvent dichloromethane: methanol (2:1) and stir at 1500 rpm on a magnetic stirrer for 30 min until all dissolved to prepare a suspension solution with a solid content of 20 mg / ml. Pipette 20 μl of each prescription solution onto a glass slide, disperse the droplets with a cover glass, dry the solution at 50 ° C, and observe using a polarizing microscope PLM. Eudragit L100-55 was tested using XRPD. The results are shown in Table 2:
[0231] Table 2
[0232] Carrier material PLM / XRPD Hydroxypropyl methylcellulose acetate succinate-LG PLM has no obvious birefringent particles Hydroxypropyl methylcellulose acetate succinate-MG PLM has very small amount of birefringent particles Hydroxypropyl methylcellulose acetate succinate-126G PLM has very small amount of birefringent particles Copolyvinylpyrrolidone VA64 PLM has very small amount of birefringent particles Copolyvinylpyrrolidone S630 PLM has very small amount of birefringent particles Povidone K29 / 32 PLM has very small amount of birefringent particles Hydroxypropylcellulose EXF PLM has very small amount of birefringent particles Hydroxypropyl methylcellulose E4M The viscosity is too high, not applicable Polyethylene glycol 6000 There are obvious undissolved matter / PLM has a large number of fine birefringent particles Hydroxypropyl methylcellulose phthalate PLM has very small amount of birefringent particles Eutectic L100-55 No obvious crystal diffraction peaks were found in XRPD detection
[0233] Table 2 shows that among the carrier substances tested, polyethylene glycol and hypromellose E4M are obviously not suitable, and other types of carriers can completely crystallize compound A.
[0234] Example 3
[0235] According to the solid dispersion preparation method described above, dichloromethane:methanol (2:1) was used as the solvent system, and different carriers and compound A were used to prepare the following solid dispersions (ASD):
[0236]
[0237]
[0238] Using dichloromethane:methanol (3:1) as the solvent system, different carriers and compound A were used to prepare the following solid dispersions (ASD):
[0239]
[0240] Note: "External addition" means that the substance is added to the solid dispersion prepared using the carrier and compound A listed in the table; *The final ratio of compound A to HPMCAS-LG is 1:7.
[0241] The experimental results show that the yields of compound A solid dispersions prepared using different carriers and drug-loading ratios are all above 75%, and are all preparable.
[0242] Example 4
[0243] According to the X-ray powder diffraction (XRPD) and polarizing microscope (PLM) determination methods described herein, the crystal transformation of compound A in the solid dispersion of the present invention was investigated. The results are shown in Table 3 and Figure 2 , 3A , 3B, 3C:
[0244] Table 3
[0245]
[0246] Table 3 shows that when HPMCAS-LG, copovidone VA64, hydroxypropylcellulose EXF and / or Eudragit L100-55 are used as carriers to prepare solid dispersions, compound A can be completely crystallized without obvious crystals.
[0247] The PLM test results in Table 3 show that only a very small amount of birefringent particles were observed in the solid dispersions with different drug loading ratios. The XRPD results also show that all samples have no crystal diffraction peaks of compound A, indicating that compound A can be completely crystallized at different drug loading ratios.
[0248] The dynamic crystallization of the representative solid dispersion of the present invention in FeSSIF-V2 solution and / or FsSSIF-V2 solution was also investigated, wherein each solid dispersion was dispersed in FeSSIF-V2 solution to prepare a suspension containing about 1 mg / mL of compound A, or dispersed in FaSSIF-V2 solution to prepare a suspension containing about 2 mg / mL of compound A; each suspension was placed in a magnetic stirrer for preliminary dispersion, dispersed at room temperature at 1500 rpm, stirred at 1000 rpm, sampled 1.5 ml at a fixed time point, and observed according to the polarizing microscope (PLM) determination method described herein. The results are shown in Table 4:
[0249] Table 4
[0250]
[0251]
[0252] Table 4 shows that each solid dispersion (ASD-11, ASD-12, ASD-13) prepared using HPMCAS-LG as a carrier and compound A can remain stable in FeSSIF-V2 solution for about 6 hours, and no obvious birefringent particles are observed in PLM inspection, and no crystal transformation occurs. Longer stability in FeSSIF-V2 solution can be achieved by adding specific polymers to the solid dispersion. For example, the addition of HPMC-E4M, SDS and HPMCAS-LG failed to improve the stability after a long time in the solution. A large number of birefringent particles (ASD-14, ASD-15, ASD-16) can still be observed after 19 hours. However, the addition of Eudragit L100-55 to the ASDs of various drug loading ratios enables the solid dispersion to remain stable in FeSSIF-V2 solution for up to 24 hours, and no obvious birefringent particles appear in PLM inspection, and no crystal transformation occurs.
[0253] Table 4 also shows that solid dispersions (ASD-4, ASD-5, ASD-6, ASD-7 and ASD-8) can also be prepared using Eudragit L100-55 or (Eudragit L100-55+HPMCAS-LG) as carriers with compound A. This group of solid dispersions remained stable in FeSSIF-V2 solution for 24 hours, and no obvious birefringent particles were observed in the PLM inspection, and no crystal transformation occurred. In addition, this group of solid dispersions also remained stable in FaSSIF-V2 solution for 24 hours, and no obvious birefringent particles were observed in the PLM inspection at each time point, and no crystal transformation occurred.
[0254] The crystal transformation of compound A in the solid dispersions of the present invention (ASD-10, ASD-11, ASD-12 and ASD-13) with different drug loading ratios was also investigated according to the modulated differential scanning calorimetry (mDSC) method described herein. The results are as follows: Figures 4A to 4D As shown, none of the samples showed the crystal peak of compound A. As the drug loading ratio decreased, the glass transition temperature decreased and the intensity of the crystal transition peak around 230°C weakened.
[0255] Example 5
[0256] According to the general experimental method described above, the dynamic solubility of the solid dispersion of the present invention in each solution was investigated using FaSSIF, FeSSIF and SGF solutions, wherein each solid dispersion was dispersed in FeSSIF-V2 solution to prepare a suspension containing about 1 mg / mL of compound A, or dispersed in FaSSIF-V2 solution to prepare a suspension containing about 2 mg / mL of compound A. Each suspension was stirred and dispersed, 1 to 1.5 ml was sampled at a fixed time point, centrifuged, the supernatant was taken, the membrane was filtered, and the content of compound A was determined by HPLC according to the general experimental method described above. The results are shown in Tables 5 and Figure 5A , Figure 5B .
[0257] Table 5
[0258]
[0259]
[0260] *: The API concentration of FeSSIF-V2 suspension is 2 mg / ml.
[0261] Table 5 shows that in the FaSSIF-V2 solution, the dissolution amount of the solid dispersions of Compound A with different carriers and different drug loading ratios at each time point is much greater than the dissolution amount of the raw material of Compound A, and the 24-hour dissolution amount of the solid dispersions of Compound A with different drug loading ratios is basically similar.
[0262] Table 5 also shows that in FaSSIF-V2 solution, the API solubility of the solid dispersions prepared with HPMCAS and / or Eudragit L100-55, or copolyvidone VA64 remains stable or increases over time, among which the API solubility of the solid dispersions prepared with HPMCAS and Eudragit L100-55 has a greater advantage over the API solubility of the solid dispersions prepared with copolyvidone VA64 and hydroxypropylcellulose EXF.
[0263] Table 5 also shows that in FaSSIF-V2 solution and FeSSIF-V2 solution, the solubility of API in the solid dispersion with internal or external addition of Eudragit L100-55 increased to varying degrees compared with the solid dispersion with HPMCAS as the polymer carrier only.
[0264] Table 5 also shows that in the FeSSIF-V2 solution, the lower the drug loading, the greater the dissolution amount, and the dissolution amount of the solid dispersion whose polymer carrier is only HPMCAS is significantly reduced in 24 hours. However, the addition of Eudragit L100-55 to the solid dispersion can keep the dissolution amount basically balanced over time, and as the addition ratio of Eudragit L100-55 increases, the dissolution amount of API also increases accordingly.
[0265] The comparison results in Table 5 also show that, when other conditions are kept the same, the amount of API dissolved in the FeSSIF-V2 solution is basically the same whether Eudragit L100-55 is added internally or externally.
[0266] In addition, the solid dispersion of the present invention was formulated into a suspension containing about 2 mg / mL of compound A using SGF solution, and the dynamic solubility was investigated. The results showed that the API solubility of solid dispersions with different drug loading ratios (e.g., ASD10-13) at each time point during the period of 1 to 24 hours was less than 0.005 mg / ml, and even less than 0.0001 mg / ml.
[0267] Example 6
[0268] The solid dispersion ASD-12 (API:HPMCAS-LG=1:3) prepared in Example 3 was placed under high temperature (60°C), high humidity (25°C / RH90%±5%) and accelerated (40°C±2°C / RH75%±5%) conditions for 0 / 5 / 10 / 30 days, and samples were taken. The chemical stability of ASD was evaluated based on purity and related substances (maximum single impurity and total impurities). The results are shown in Table 6.
[0269] Table 6
[0270]
[0271] Table 6 shows that under high temperature, high humidity and accelerated conditions, the appearance of ASD has no obvious change, and the related substances have no obvious increase, indicating that ASD has good chemical stability.
[0272] In addition, the solid form stability (mDSC, XRPD and PLM) of the solid dispersion ASD-1 samples taken at the above-mentioned time points was also investigated. The results showed that at 30 days, no obvious crystal diffraction was found in the XRPD spectra of all samples, no obvious birefringent particles were found in the PLM examination, and: the mDSC spectra of all condition samples had no significant changes compared with the 0th day.
[0273] In addition, the content, impurities (single impurity and total impurities) and solid form stability (mDSC, XRPD and PLM) of the solid dispersion ASD-1 samples on the 0th, 5th, 10th and 30th days were investigated under the conditions of refrigeration (2-8°C), grinding for 5 minutes (room temperature), grinding for 5 minutes and refrigeration (2-8°C), grinding for 15 minutes (room temperature), grinding for 15 minutes and refrigeration (2-8°C), tableting (room temperature), tableting and refrigeration (2-8°C), tableting with PH102 at room temperature (solid dispersion: PH102 = 1:5), and tableting with PH102 at 2-8°C (solid dispersion: PH102 = 1:5). The results showed that there was no significant change in the content and impurities of the samples under each experimental condition, no obvious crystal diffraction was found in the XRPD spectra of all samples, no obvious birefringent particles were found in the PLM inspection, and: the mDSC spectra of the samples under all conditions did not change significantly from the 0th day.
[0274] The above results show that the solid dispersion of the present invention has satisfactory stability properties and exhibits excellent chemical stability and solid-state stability under all tested conditions, making it potentially developable into a practical and convenient formulation product.
[0275] Example 7
[0276] In this experiment, a 2.5 mg / ml solution of compound A in a 0.5% SDS aqueous solution was used as a control (prepared within 2 hours before use) to investigate the pharmacokinetic properties of the solid dispersion of the present invention (ASD-22, filled in a capsule shell) in beagle dogs.
[0277] Specifically, 15 beagle dogs (male, weighing about 8-11 kg) were randomly divided into 5 groups, 3 in each group. After fasting for one night, two of the groups were orally administered with the test sample, at doses of 2.5 mg / kg and 10 mg / kg, respectively, and another group of beagle dogs were orally administered with 10 mg / kg of the test sample after eating for 0.5 h; the other two groups of beagle dogs that had fasted for one night were orally administered with 2.5 mg / kg and 50 mg / kg of compound A solution as controls. 0.5 ml of blood was collected from the cephalic vein before administration (0 h) and 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h after administration. After the blood sample was taken, it was immediately placed in a heparinized EP tube, centrifuged at 3000 g (RCF: relative centrifugal force) for 5 min, and the plasma was separated and frozen and stored in a -70°C refrigerator for testing.
[0278] During the determination, after the plasma was thawed, 20 μL was accurately drawn into a stoppered centrifuge tube, 200 μL of internal standard solution (60 ng / mL diclofenac 70% methanol aqueous solution) was accurately added, vortexed for 10 minutes, centrifuged at 5800 rpm for 10 minutes, and the supernatant was taken for LC-MS / MS analysis (Waters ACQUITY UPLC BEH C18 2.1×50 mm; mobile phase A: 0.025% formic acid (1 mM ammonium acetate aqueous solution) solution, mobile phase B: 0.025% phosphoric acid (1 mM ammonium acetate methanol solution) solution; gradient: 10% B 0.2 min, 0.2-1 min rise to 95% B, keep 0.5 min, 1.50-1.51 min drop to 10% B, keep to 2 min; flow rate 0.60 mL / min; automatic sampler temperature control / column temperature 5°C / 60°C; injection volume 4 μL)
[0279] The main pharmacokinetic parameters are shown in Table 7, and the plasma drug concentration-time curve is shown in Figure 6 , where the AUC value was calculated using WinNonLin software.
[0280] Table 7
[0281]
[0282] Table 7 and Figure 6 The results show that the solid dispersion of the present application has the same exposure in beagle dogs as the solution under the same dosage and conditions, and no obvious food effect is observed. This shows that compound A, which is almost insoluble in water, has been successfully prepared into a solid form with a bioavailability equivalent to that of the solution, overcoming the common defect of low bioavailability of poorly soluble drugs and expanding the application space of drugs.
[0283] Example 8
[0284] The solid dispersion of the present invention (ASD-12) is mixed uniformly with the excipients shown in Table 8 below, sieved, and dry granulated. The obtained granules are mixed uniformly with magnesium stearate, and the obtained total mixed granules are pressed into tablets.
[0285] Table 8
[0286]
[0287]
[0288] Table 8 shows that the tablets of prescriptions T1, T3, T4, and T5 exhibit good dissolution characteristics, with dissolution reaching more than 80% in 45 minutes. In particular, the tablets prepared using microcrystalline cellulose alone as a filler have the best overall performance, good compressibility, acceptable disintegration time, and the most complete dissolution.
[0289] The solid dispersion of the present invention (ASD-12) was mixed uniformly with the excipients according to the formulation shown in Table 9 below, sieved, and dry granulated. The obtained granules were mixed uniformly with magnesium stearate, and the obtained total mixed granules were pressed into tablets.
[0290] Table 9
[0291]
[0292] *: The pressure of dry granulation is 5-6KPa, and the others are 6-8KPa.
[0293] Each tablet prepared by the above prescription has an acceptable off-white (occasionally spotted) appearance.
[0294] Table 9 shows that the content of disintegrant is proportional to the disintegration time. About 1 to 10 wt % of the disintegrant cross-linked carboxymethyl cellulose sodium can make the preparation disintegrate rapidly, and the disintegration time is within 1 to 10 minutes. Among them, the disintegration time of about 2 to 8 wt %, especially about 3 to 7 wt % of the disintegrant is the most moderate. In addition, the granules of the dry granulation of each formulation have moderate hardness, friability (4 min) is between about 0.05 and 0.15%, and friability (8 min) is between about 0.1 and 0.3%.
[0295] Table 9 also shows that the tested binder content range can make the hardness of dry granules moderate, among which about 1-3% by weight of binder is preferred, and about 1.5-2.5% by weight of binder is most preferred. The compressed tablets have good formulation properties, such as friability less than 0.2% by weight and moderate disintegration time.
[0296] The preparation experiment process shows that adding the above-prescribed amount of magnesium stearate to the dry granulation initial mixed powder and performing dry granulation after mixing can help improve the adhesion phenomenon. Adding the prescribed amount of magnesium stearate after dry granulation and performing tableting after mixing can help improve the sticking phenomenon.
[0297] In addition, the prescription T15 in the above table was used, and the dry granulation pressure was changed from 6-8KPa to 4-6KPa. It was observed that the granules basically did not stick to the rollers and had good fluidity after granulation, the tablets did not stick to the punches, the tablet surface was flat and smooth, the friability was qualified (all less than 0.1%), the disintegration time was less than 10 minutes (the disintegration time of 50mg tablets was 6min8s, and the disintegration time of 200mg tablets was 3min), the dissolution in 45 minutes (pH6.8+0.1% SDS) reached 89.1% (50mg tablets) and 90.7% (200mg tablets), and the dissolution in 60 minutes (pH6.8+0.1% SDS) reached 93.9% (50mg tablets) and 91.7% (200mg tablets).
[0298] Example 9
[0299] Based on the results of Example 8, the solid dispersion of the present invention, together with a stabilizer, a filler, a binder, a disintegrant, a glidant, a lubricant, and a film coating premix, were formulated into tablets of 10 mg, 50 mg, and 200 mg, respectively, and their tablet properties were examined.
[0300] Specifically, according to Table 10 below, the solid dispersion ASD-12, methacrylic acid-ethyl acrylate copolymer (e.g. Eudragit L100-55), microcrystalline cellulose, hypromellose, cross-linked carboxymethyl cellulose sodium, colloidal silicon dioxide and film coating premix, and magnesium stearate, are sieved (50-60 mesh); ASD-12, methacrylic acid-ethyl acrylate copolymer, microcrystalline cellulose, hypromellose, cross-linked carboxymethyl cellulose sodium, and colloidal silicon dioxide are mixed in a mixer and sieved, and this step can be repeated once more (premix); then internal magnesium stearate (about 0.5% w / w) is added and mixed uniformly; the premix with added magnesium stearate is added to a dry granulator for dry granulation, and the pressure is controlled at 4-6KPa; the prepared granules are mixed uniformly with the remaining magnesium stearate (about 0.5% w / w), the obtained total mixed granules are pressed into tablets, and the appearance, friability, hardness, dissolution properties and stability of the obtained tablets are examined.
[0301] Table 10
[0302]
[0303] Note: The dissolution data in brackets in the table were obtained by testing in pH 6.8 + 0.1% SDS.
[0304] Table 10 shows that the poorly soluble compound A is prepared into a solid dispersion according to the present invention, and further prepared into an oral solid preparation according to the present invention, and its dissolution performance is excellent (see Table 10). Figure 7 ), and shows good various formulation properties, and is expected to provide anticancer drugs with enhanced bioavailability, thereby being able to exert therapeutic efficacy at a lower dose, meeting the medical needs in the field of cancer treatment.
[0305] In addition, the stability of the above-mentioned 10mg, 50mg and 200mg tablets packaged with common packaging materials (such as 45ml or 100ml high-density polyethylene bottles for medicine, 33mm or 38mm polyethylene / polypropylene child-safe combination bottle caps for medicine) at 40℃±2℃ / RH75%±5% and 30℃±2℃ / RH65%±5% was investigated. The appearance, moisture, related substances, content and dissolution of the tested samples were checked. The results showed no significant changes, indicating that the prepared tablet preparations have good stability and good compatibility with the packaging materials. The results are shown in Table 11:
[0306] Table 11
[0307]
[0308]
[0309] The solubility value represents the experimental result after 45 minutes in pH 6.8 phosphate buffer + 0.15% sodium dodecyl sulfate medium; the "related substances" value is the sum of all impurities in the HPLC spectrum under the HPLC detection conditions described in the general experimental method; and the "water content" is the result determined by the Karl Fischer method.
[0310] The specific embodiments given herein are only used to illustrate the present invention and do not constitute a limitation on the scope defined by the claims. Based on the contents disclosed in this application, those skilled in the art can obviously understand the equivalent variants of the technical solution of this application, and these variants are also included in the scope of this application.
Claims
1. A solid dispersion comprising an EED inhibitor or a pharmaceutically acceptable salt or solvate thereof, and a polymer carrier, wherein the EED inhibitor is a compound of the following formula: in: R 1 is an aralkyl group; R 2 Selected from H and C 1 -C 4 alkyl; X is selected from -C(R 5a )(R 5b )-, -C(=O)- and -S(=O) 2 -; R 5a and R 5b Independently selected from H and C 1 -C 4 alkyl; Y is selected from -C(R 6a )(R 6b )-, -S-, -O- and -N(R 7 )-; Z is -C(R 6c )(R 6d ) m -; R 6a and R 6b Independently selected from H and C 1 -C 4 alkyl; R 6c and R 6d Each independently selected from H and C 1 -C 4 Alkyl; m is 0, 1 or 2; R 7 Selected from C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, optionally substituted C 3 -C 8 Cycloalkyl; L is selected from -C(R 8b )= and -N=; R 8a Selected from -CF 3 、-CH 3 , -CHF 2 、-CD 3 and cyclopropyl; and R 8b and R 8c is hydrogen; or a pharmaceutically acceptable salt or solvate thereof.
2. The solid dispersion of claim 1, wherein the EED inhibitor is compound A: or a pharmaceutically acceptable salt or solvate thereof.
3. The solid dispersion according to claim 1 or 2, wherein the polymer carrier is selected from cellulose ether esters, preferably hypromellose acetate succinate.
4. The solid dispersion according to claim 1 or 2, wherein the polymer carrier is selected from polyacrylic acid resins, preferably methacrylic acid-ethyl acrylate (1:1) copolymer, preferably Eudragit L100-55.
5. The solid dispersion of claim 1 or 2, wherein the polymer carrier is a mixture of cellulose ether ester and polyacrylic acid resin, preferably a mixture of hydroxypropyl methylcellulose acetate succinate and a copolymer of methacrylic acid and ethyl acrylate (1:1), more preferably a mixture of hydroxypropyl methylcellulose acetate succinate and Eudragit L100-55.
6. The solid dispersion of any one of claims 1 to 5, wherein the weight ratio of the EED inhibitor or a pharmaceutically acceptable salt or solvate thereof to the polymer carrier is about 1:1 to 1:
5.
7. An oral solid preparation comprising the solid dispersion according to any one of claims 1 to 6 and one or more pharmaceutically acceptable excipients.
8. The oral solid preparation according to claim 7, which is a tablet, comprising the solid dispersion according to any one of claims 1 to 6 and one or more of a filler, a binder, a disintegrant, a lubricant, a glidant, a stabilizer and a coating agent.
9. The oral solid preparation according to claim 7 or 8, wherein the pharmaceutically acceptable excipients are fillers, binders, disintegrants, lubricants, glidants and stabilizers.
10. The oral solid preparation according to any one of claims 7 to 9, wherein the content of the EED inhibitor is about 10 to 30% by weight, preferably about 10 to 20% by weight.
11. The oral solid dosage form according to any one of claims 7 to 9, wherein the solid dispersion accounts for about 30 to 80% by weight of the oral dosage form, preferably about 50 to 70% by weight.
12. The oral solid preparation according to any one of claims 7 to 9, comprising 1) about 30-80% by weight of the solid dispersion, comprising about 10-200 mg of the EED inhibitor and the polymer carrier; 2) about 20 to 40 weight percent of a filler; 3) about 1 to 3 weight percent of a binder; 4) about 2 to 8 weight percent of a disintegrant; 5) about 0.5 to 2 weight percent of a lubricant; 6) about 2-8 wt % of a stabilizer; and 7) About 0.5 to 2% by weight of a glidant.
13. The oral solid preparation according to any one of claims 7 to 9, comprising 1) about 50-70% by weight of the solid dispersion, comprising about 10-200 mg of the EED inhibitor and the polymer carrier; 2) about 20 to 30 weight percent of a filler; 3) about 1.5 to 2.5 weight percent of a binder; 4) about 3 to 7 weight percent of a disintegrant; 5) about 0.5 to 1.5 weight percent of a lubricant; 6) about 4 to 8 weight percent of a stabilizer; and 7) About 0.5-1.5% by weight of a glidant.
14. The oral solid formulation according to any one of claims 8 to 13, wherein the EED inhibitor is compound A or a pharmaceutically acceptable salt or solvate thereof, and the polymer carrier in the solid dispersion is selected from hydroxypropyl methylcellulose acetate succinate, methacrylic acid-ethyl acrylate (1:1) copolymer or a mixture of the two.
15. The oral solid dosage form according to any one of claims 8 to 14, wherein the stabilizer is a methacrylic acid-ethyl acrylate (1:1) copolymer, preferably Eudragit L100-55.
16. The oral solid preparation according to any one of claims 8 to 15, wherein the filler is microcrystalline cellulose, the binder is hypromellose, the disintegrant is croscarmellose sodium, the lubricant is magnesium stearate, and the glidant is colloidal silicon dioxide.
17. Use of a solid dispersion according to any one of claims 1 to 6 or a solid oral dosage form according to any one of claims 7 to 16 for treating or preventing a disease for which inhibition of EED provides a benefit.
18. Use of a solid dispersion according to any one of claims 1 to 6 or a solid oral dosage form according to any one of claims 7 to 16 in the preparation of a medicament for the treatment or prevention of a disease for which inhibition of EED provides a benefit.
19. A method of treating or preventing a disease in a patient in need thereof for which inhibition of EED provides a benefit, comprising administering to said patient a therapeutically effective amount of a solid dispersion of any one of claims 1 to 6 or a solid oral dosage form of any one of claims 7-16.
20. The use of claim 17 or 18 or the method of claim 19, wherein the disease that benefits from EED inhibition is a cancer selected from acute monocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia mixed lineage leukemia, NUT-midline carcinoma, multiple myeloma, small cell lung cancer, non-small cell lung cancer, neuroblastoma, Burkitt's lymphoma, cervical cancer, esophageal cancer, ovarian cancer, colorectal cancer, prostate cancer, breast cancer, bladder cancer, ovarian cancer, glioma, sarcoma, esophageal squamous cell carcinoma and papillary thyroid carcinoma.
Citation Information
Patent Citations
Imidazopyrimidines as EED inhibitors and uses thereof
CN114127073A
